



PATENT
Attorney Docket No. 402090

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

MISHRA et al.

Group Art Unit: 1617

Application No. 09/376,487

Examiner: E. Webman

Filed: August 18, 1999

For: INJECTABLE AQUEOUS DISPERSION
OF PROPOFOL

#25

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form 1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

The Information Disclosure Statement is being filed:

- ☒ **within** any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 of an international application; (c) before the mailing date of a first Office Action on the merits; or (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

- ☐ **after** (a), (b), (c) or (d) above, but before the mailing date of a final action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and includes *one* of:
- ☐ the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below).
- or*
- ☐ the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below).
- ☐ **after** the mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and on or before payment of the issue fee, and includes the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below).
- ☐ **after** the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before payment of the issue fee, and **within** thirty days of receiving each item of information contained in the Information Disclosure Statement, and includes the Statement under 37 CFR 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below).

NOTE: This is for original applications except applications for a design patent, filed on or after May 29, 2000, wherein a paper containing only an Information Disclosure Statement in compliance with 37 CFR 1.97 and 1.98 is being filed.

Copies of the References

- ☒ Copies of the references listed on the enclosed Form 1449 are enclosed herewith. Attached to each reference not in the English language is a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3). An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3).
- ☐ A copy of the foreign search report is enclosed herewith.
- ☐ The references listed on the enclosed Form 1449 were previously identified in the parent application(s) of the present application, and copies of the references were furnished at that time. Accordingly, additional copies of the references are not submitted herewith, so as not to burden the file with duplicate copies of references. The Examiner is respectfully requested to carefully review the references in accordance with the requirements set out in the Manual of Patent Examining Procedure. In accordance with 37 CFR 1.98(d), the details of the parent application(s) relied upon for an earlier filing date under 35 USC 120 in which copies of the references were previously furnished are set out below:

| U.S. APPLICATIONS | | Status (<i>check one</i>) | | |
|-------------------|------------------|-----------------------------|---------|-----------|
| U.S. APPLICATIONS | U.S. FILING DATE | PATENTED | PENDING | ABANDONED |
| 1. | | | | |
| 2. | | | | |
| 3. | | | | |

Statement under 37 CFR 1.97(e)

- ☐ The **undersigned** hereby states that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.
- ☐ The **undersigned** hereby states that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

Statement under 37 CFR 1.704(d)

- ☐ The **undersigned** hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

Fees

- ☒ **No fee** is owed by the applicant(s).
- ☐ The **IDS Fee of \$180** under 37 CFR 1.17(p) is enclosed herewith.

Method of Payment of Fees

- ☐ Attached is a check in the amount of \$.
- ☐ Charge Deposit Account No. 12-1216 in the amount of \$. (A duplicate copy of this communication is enclosed for that purpose.)

Authorization to Charge Additional Fees

- ☒ If any additional fees are owed in connection with this communication, please charge Deposit Account No. 12-1216. (A duplicate copy of this communication is enclosed for that purpose.)

In re Appln. of Mishra et al.
Application No. 09/376,487

Instructions as to Overpayment


☒ Credit Account No. 12-1216.
☐ Refund

Respectfully submitted,



Leah Robinson, Reg. 44,990
LEYDIG, VOIT & MAYER
700 Thirteenth Street, N.W., Suite 300
Washington, DC 20005-3960
(202) 737-6770 (telephone)
(202) 737-6776 (facsimile)

Date: 12/4/02
LCO:ves

Please type a plus sign (+) inside this box → 




| | | | | | |
|---|---|-----------------|---|--------------------------|--|
| Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| Application Number | | 9/376,487 | | | |
| Filing Date | | August 18, 1999 | | | |
| First Named Inventor | | MISHRA | | | |
| Group Art Unit | | 1617 | | | |
| Examiner Name | | E. Webman | | | |
| Attorney Docket Number | | 402090 | | | |
| Sheet | 1 | of | 2 | | |


| U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------|----------|---------------------------------|--------------|-------------------------------|------------------------|-------------------------------|
| Examiner Initials | Doc. No. | U.S. Patent Document | | Name of Patentee or Applicant | Date of Publication | Filing Date If Appropriate |
| | | Application or Patent Number | Kind Code | | | |
| | 1 | 4,056,635 | | Glen et al. | 11/1/1977 | |
| | 2 | 4,280,996 | | Okamoto et al. | 7/28/1981 | |
| | 3 | 4,309,421 | | Ghyczy et al. | 1/5/1982 | |
| | 4 | 4,340,594 | | Mizushima et al. | 7/20/1982 | |
| | 5 | 4,687,762 | | Fukushima et al. | 8/18/1987 | |
| | 6 | 4,837,028 | | Allen | 6/6/1989 | |
| | 7 | 4,880,634 | | Speiser | 11/14/1989 | |
| | 8 | 4,895,726 | | Curtet et al. | 1/23/1990 | |
| | 9 | 5,023,087 | | Yau-Young | 6/11/1991 | |
| | 10 | 5,100,591 | | Leclef et al. | 3/31/1992 | |
| | 11 | 5,320,906 | | Eley et al. | 6/14/1994 | |
| | 12 | 5,527,537 | | Dietl | 6/18/1996 | |
| | 13 | 5,827,520 | | de Salvart | 10/27/1998 | |
| | 14 | 5,827,536 | | Laruelle | 10/27/1998 | |
| | 15 | 5,880,148 | | Edgar et al. | 3/9/1999 | |
| | 16 | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|----------|-------------------------|---------------------------------|--------------|-------------------------------|------------------------|-------------|------|
| Examiner Initials | Doc. No. | Foreign Patent Document | | | Name of Patentee or Applicant | Date of Publication | Translation | |
| | | Office | Application or Patent Number | Kind Code | | | Yes | No** |
| | 17 | DE | 25 13 797 | | ICI Ltd. | 10/9/975 | | X+ |
| | 18 | DE | 29 38 807 | | Green Cross Corp. | 11/13/1980 | | X+ |
| | 19 | DE | 3421 468 | | Rentschler Arzenimittel | 12/19/1985 | | X+ |
| | 20 | EP | 052 322 | | Gersonde Klaus Prof Dr | 5/26/1982 | | X+ |
| | 21 | EP | 057 829 | | Fullard | 8/18/1982 | | |
| | 22 | EP | 272 091 | | Vestar, Inc. | 6/22/1988 | | |
| | 23 | EP | 330 532 | | Fournier Innovation Synergie | 8/30/1989 | | X+ |
| | 24 | EP | 391 369 | | Yissum Research Dev. | 10/10/1990 | | |
| | 25 | EP | 418 153 | | Medgenix Group SA | 3/20/1991 | | X+ |
| | 26 | EP | 456 670 | | Braun Melsungen AG | 11/21/1991 | | X+ |
| | 27 | EP | 456 764 | | Braun Melsungen | 11/21/1991 | | X+ |
| | 28 | EP | 499 299 | | Sterling Winthrop Inc. | 8/19/1992 | | |
| | 29 | EP | 535 567 | | Braun Melsungen AG | 4/7/1993 | | X+ |
| | 30 | EP | 570 829 | | Hans | 11/24/1993 | | X+ |
| | 31 | EP | 601 618 | | Sterling Winthrop Inc. | 6/15/1994 | | |
| | 32 | EP | 602 700 | | Sterling Winthrop Inc. | 6/22/1994 | | |
| | 33 | EP | 724 877 | | Fournier Lab SA | 8/7/1996 | | X+ |
| | 34 | EP | 757 911 | | CLL Pharma | 2/12/1997 | | X+ |
| / | 35 | EP | 770 387 | | B. Braun Melsungen AG | 5/2/1997 | | |
| | 36 | EP | 770 381 | | Oreal | 5/2/1997 | | X+ |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box → 



Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

| | |
|------------------------|-----------------|
| Application Number | 9/376,487 |
| Filing Date | August 18, 1999 |
| First Named Inventor | MISHRA |
| Group Art Unit | 1617 |
| Examiner Name | E. Webman |
| Attorney Docket Number | 402090 |

FOREIGN PATENT DOCUMENTS

| Examiner Initials | Doc. No. | Foreign Patent Document | | | Name of Patentee or Applicant | Date of Publication | Translation | |
|-------------------|----------|-------------------------|------------------------------|-----------|-----------------------------------|---------------------|-------------|------|
| | | Office | Application or Patent Number | Kind Code | | | Yes | No** |
| | 37 | EP | 814 787 | | AstraZeneca AB | 1/7/1998 | | |
| | 38 | EP | 1 238 677 | | AstraZeneca AB | 9/11/2002 | | |
| | 39 | FR | 2 265 357 | | ICI Ltd. | 10/24/1975 | | X+ |
| | 40 | FR | 2 617 047 | | Sanofi SA/Fournier Labs. | 12/30/1988 | | X+ |
| | 41 | JP | 55-141407 | | Nattermann A & CIE | 11/5/1980 | | X+ |
| | 42 | JP | 56-167616 | | Green Cross Corp. | 12/23/1981 | | X+ |
| | 43 | JP | 60-208910 | | Green Cross Corp. | 10/21/85 | | X+ |
| | 44 | JP | 63-502117 | | | 8/18/1988 | | X+ |
| | 45 | JP | 63-233915 | | Besutaa Res. Inc. | 9/29/1988 | | X+ |
| | 46 | JP | 1-502590 | | Liposome Tech. Inc. | 9/7/1989 | | X+ |
| | 47 | HU | 211 580 | | Egis Gyogyszergyar Rt. | 12/28/1995 | | X+ |
| | 48 | PCT | WO 85/00011 | | The University of Miami | 1/3/1985 | | |
| | 49 | PCT | WO 87/04592 | | Liposome Tech. Inc. | 8/13/1987 | | |
| | 50 | PCT | WO 91/04011 | | Riker Labs., Inc. | 4/4/1991 | | |
| | 51 | PCT | WO 93/19736 | | Kabi Pharmacia AB | 10/14/1993 | | |
| | 52 | PCT | WO 94/20072 | | Pharmacia AB | 9/15/1994 | | |
| | 53 | PCT | WO 96/01637 | | Astra Aktiebolag | 1/25/1996 | | |
| | 54 | PCT | WO 96/19064 | | Xcellenet, Inc. | 6/20/1996 | | |
| | 55 | PCT | WO 96/21439 | | Galephar P.R. Inc. | 7/18/1996 | | |
| | 56 | PCT | WO 96/29064 | | Zeneca Ltd. | 9/26/1996 | | |
| / | 57 | PCT | WO 97/10814 | | Vesifact AG | 3/27/1997 | | |
| | 58 | PCT | WO 97/14407 | | Research Triangle Pharmaceuticals | 4/24/1997 | | |
| / | 59 | PCT | WO 98/53805 | | Saucy Ltd. | 12/3/1998 | | |
| | 60 | PCT | WO 99/39696 | | Gensia Sicor Inc. | 8/12/1999 | | |
| | 61 | PCT | WO 00/10531 | | RTP Pharma Inc. | 3/2/2000 | | |
| | 62 | PCT | WO 00/24376 | | Abbott Labs. | 5/4/2000 | | |
| | 63 | PCT | WO 00/54588 | | Krusz | 9/21/00 | | |
| / | 64 | PCT | WO 00/59471 | | Baxter International, Inc. | 10/12/2000 | | |
| / | 65 | PCT | WO 00/59472 | | Baxter International, Inc. | 10/12/2000 | | |
| / | 66 | PCT | WO 00/78301 | | Kuhnle Pharm. Co. Ltd. | 12/28/2000 | | |
| | 67 | PCT | WO 01/30372 | | BASF Aktiengesellschaft | 5/3/2001 | | X+ |
| | 68 | PCT | WO 02/21517 | | Zeon Corp. | 3/14/2002 | | X+ |
| | 69 | UK | 2 046 094 | | A. Nattermann & Cie | 11/12/1980 | | |
| | 70 | UK | 2 250 197 | | Egis Gyogyszergyar | 6/3/1992 | | |
| | 71 | UK | 2 298 789 | | Zeneca Ltd. | 9/18/1996 | | |

Examiner Signature

Date Considered

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).